Interactive Infographic to Educate Clinicians on Novel Approaches to Immunotherapy in Advanced Esophageal Squamous Cell Carcinoma

Interactive Infographic to Educate Clinicians on Novel Approaches to Immunotherapy in Advanced Esophageal Squamous Cell Carcinoma
Contact: Matt Miller
Phone: 646-336-6495
Fax: 646-336-6497
Email: [email protected]

NEW YORK (9/1/2021) – DKBmed, LLC is developing an interactive infographic to educate clinicians on advances in the therapeutic paradigm for patients with esophageal carcinoma. The program, entitled Oncology Innovations: Novel Approaches to Immunotherapy in mESCC, will depart from traditional activity delivery formats and will grant learners the ability to personalize their learning experience.

Approximately 18,440 individuals in the United States are diagnosed with esophageal cancer each year, with one in four patients receiving a diagnosis in the cancer’s advanced stage. Histologically, esophageal cancers can be classified as adenocarcinoma (AEG) or squamous cell carcinoma (ESCC). AEG predominantly affects Caucasian populations, whereas ESCC manifests more commonly among African Americans, the young, and individuals from lower socioeconomic backgrounds. This demographic disparity may, in part, explain clinicians’ relative unfamiliarity with ESCC.

“Esophageal squamous cell carcinomas are a rarer sight in this country,” explains Yelena Janjigian, MD, a medical oncologist who specializes in esophageal carcinoma at Memorial Sloan Kettering Cancer Center. “Most of the education that takes place is for adenocarcinomas, so it would be very helpful to have some education on squamous cell carcinomas.”

Treatment of esophageal cancers like ESCC generally requires a multifaceted approach, including surgery, chemotherapy, chemoradiotherapy, and most recently, immunotherapy. The advent of immunotherapy checkpoint inhibitors in recent years is a welcome development for patients, but their existence complicates clinicians’ efforts to select and sequence treatments. Additionally, only 13% of patients with esophageal cancer respond to checkpoint inhibitors, so clinicians need familiarity with a variety of care strategies. Patients with ESCC sometimes present with liver cirrhosis and reduced pulmonary function due to alcohol and smoking addictions; these serious comorbidities require careful, additional consideration on the part of clinicians.

Oncology Innovations: Novel Approaches to Immunotherapy in mESCC will organize and present key information for clinicians in a digital, interactive infographic format. This design facilitates a high degree of personalization by allowing participants to explore topics most aligned with their personal interests and needs. This online educational initiative will feature:

  • Multiple clear, simple visuals conveying central concepts
  • Layered information accessible via clickable buttons
  • Engaging, visually crisp animations
  • An engaging audio narrative
  • Supplementary links to reference materials, charts, graphs, and additional reading

About the Postgraduate Institute of Medicine

Founded in 1979, the Postgraduate Institute of Medicine (PIM) is a nationally accredited, independent provider of continuing education for healthcare professionals. PIM is a recognized leader in the field and specializes in joint providership, outcomes measurement, as well as grant solicitation and funding support. In addition to these services, PIM also offers an eLearning program with traffic guarantees available at https://www.cmeuniversity.com/. To learn more about PIM, visit their website at: https://www.pimed.com/.

About DKBmed

DKBmed is an integrated continuing medical education company operated by an experienced team of medical education experts. DKBmed provides health care professionals with effective medical education that closes identified knowledge and practice gaps to improve patient health.

Working with accredited providers and other partners, DKBmed develops innovative educational programs and quality improvement (QI) initiatives, bringing new learning methodologies to the CME landscape. DKBmed has become a leader in QI in the independent medical education space with QI projects in Pain Management, HIV, Depression, Influenza, and Diabetic Eye Disease. DKBmed was also an early adopter of case scenarios with real patients and live actors, TED/DKBmed Talks, 3D animation, webcasts, podcasts, and smart phone applications for clinicians and patients. These forward-thinking approaches enable health care professionals to learn and access educational programs in a manner that is most convenient and appropriate for them.

DKBmed’s programs are accessible through the company’s website (www.dkbmed.com). They reach more than 150,000 health care professionals in primary care and in a variety of specialties and disease states including: HIV, COVID-19, cystic fibrosis, diabetes, influenza, dermatology, retinal disease, rheumatoid arthritis, COPD, asthma, multiple sclerosis, pain management, depression and viral hepatitis (HBV, HCV) and oncology.